A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

December 8, 2025

Study Completion Date

December 8, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

CC-95266

Specified dose on specified days

DRUG

Fludarabine

Specified dose on specified days

DRUG

Cyclophosphamide

Specified dose on specified days

DRUG

Bendamustine

Specified dose on specified days

Trial Locations (10)

10016

Local Institution - 005, Birmingham

10029

Local Institution - 011, New York

21201

Local Institution - 008, Baltimore

37203

Local Institution - 001, Nashville

75390

Local Institution - 006, Dallas

80218

Local Institution - 002, Denver

94143

Local Institution - 012, San Francisco

98104

Local Institution - 003, Seattle

91010-301

Local Institution - 009, Duarte

02215

Local Institution - 010, Boston

All Listed Sponsors
lead

Juno Therapeutics, a Subsidiary of Celgene

INDUSTRY